Effect of Pentoxifylline on Prognosis of Coronavirus Disease 2019 (COVID- 19) Infection

Covid19 Clinical Trial

Official title:

Effect of Pentoxifylline on Immune-inflammation Index for Predicting Prognosis of Coronavirus Disease 2019 (COVID- 19) Infection

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04739345
• Other study ID #: COVID-Pentoxifylline
• Status: Completed
• Phase: N/A
• Start date: December 1, 2020
• Est. completion date: October 1, 2022

Study information

• Verified date: February 2023
• Source: Ain Shams University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Coronavirus disease 2019 (COVID-19) remains a threatening pandemic, due to its rapid transmission, uncertain risk factors for progression that lead to its lethality and yet unsatisfactory antiviral therapy or prophylaxis. The respiratory system remains the most frequently affected by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2), with patients either presenting mild illness as well as more severe complications such as acute respiratory distress syndrome (ARDS) that necessitates admission in Intensive Care Units (ICU). Unfortunately, the remaining patients progress to a second phase-called the inflammatory stage-featuring ARDS, thromboembolic events, and myocardial acute injury. These clinical exacerbation latter predicts poor prognosis associated with an exacerbation of the immune system cascade; a phenomenon known as "cytokine storm". In the context of COVID-19, the hyper inflammation diagnostic criteria are partly defined. Early studies of patients with COVID-19 established independent associations between biomarkers of inflammation, such as C-reactive protein, interleukin [IL]-6, ferritin and D-dimer, and severe disease states that require respiratory support or result in death.

The aim of this study was to identify practical blood immune- inflammatory biomarker / ratio that could be used alternatively to IL-6 for predicting severity of coronavirus disease 2019 (COVID- 19) in clinical practice.

Another aim is to unveil the association of the pro-inflammatory profile as categorized by the IL-6 levels in patients infected by SARS-COV-2, with disease severity and outcomes of COVID -19.

Description:

Recent research confirmed that levels of IL-6 seem are associated with COVID-19 induced inflammatory response, respiratory failure, needing for mechanical ventilation and/or intubation and mortality. The importance of identifying Il-6 as a biomarker lies in the potential use of antibody against IL-6 such as tocilizumab, which is currently used in the treatment protocol of covid-19. The authors shared an encouraging experience of utilizing tocilizumab medication, particularly in patients at risk of developing chemokine storm secondary to COVID-19. IL-6, a chemokine, is an important biomarker of inflammation and has been shown in studies as an important predictor of severe COVID-19. IL-6 is responsible for elevation of acute phase reactants, such as C-reactive protein, serum amyloid A, fibrinogen, and hepcidin, and inhibition of albumin synthesis. The dysregulated production of IL-6 has been attributed to autoimmunity and chronic inflammation.

We performed a systematic review and meta analysis to compare IL-6 in severe and non severe patients. In clinical practice, it remains crucial to develop a scoring system that includes IL-6 to assist clinicians in early recognition of patients at risk for developing severe disease.

Circulating biomarker like neutrophil (NEU)-to-lymphocyte (LYM) ratio (NLR) as well as other ratios are used to represent inflammation and the immune status and are considered a potential predictor for the prognosis of COVID-19 patients. Interestingly clinical scores like the CALL score (C = comorbidity, A= age, L = lymphocyte count, L = lactate dehydrogenase (LDH)) have been used for predicting progression towards clinical worsening.

Adding IL-6 levels to the CALL score proved to improve its predictive power and make treatment more appropriate, especially in patients for whom decision whether to treat or not with IL-6 inhibitors such as tocilizumab is required. It should be recognized that the CALL-IL-6 score could be difficult to reproduce in low- and medium-income countries due to costs of IL-6 dosage.

Aim of the Study

1. Identify new blood immune inflammatory biomarker / ratio that could be used alternatively to IL-6 for predicting severity of coronavirus disease 2019 (COVID- 19) in clinical practice.

2. Evaluate the influence of the pro-inflammatory profile on clinical outcomes and therapeutic efficacy as categorized by the IL-6 levels in patients infected by SARS-COV-2.

3. Assess potential associations with other blood inflammatory biomarker and the impact of the inflammatory status on clinical outcomes.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 69
• Est. completion date: October 1, 2022
• Est. primary completion date: June 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Age 18 to 65 years.

2. COVID-19 hospitalized patients with pneumonia proved by chest X-ray or CT scan.

3. Confirmed infection with COVID-19 virus using RT-PCR or strongly suspected to be infected with pending confirmation studies.

4. Have acute respiratory distress syndrome (ARDS).

5. Having either peripheral capillary oxygen saturation (SpO2) = 94% ambient air, or a partial oxygen pressure (PaO2) to fraction of inspired oxygen (FiO2) ratio = 300 mmHg.

Exclusion Criteria:

1. Age greater than 85 years-old

2. Creatinine clearance (CrCl) < 10ml/min.

3. Severe circulatory shock with a dose of norepinephrine higher than 1.0 µg/kg/min.

4. Pregnant women.

Related Conditions & MeSH terms

• Communicable Diseases
• Corona Virus Infection
• Coronavirus Infections
• COVID-19
• Covid19
• Cytokine Release Syndrome
• Cytokine Storm
• Infections

Intervention

Drug:
• Pentoxifylline
400 mg of pentoxifylline orally TID with the standard COVID-19 protocol of the Egyptian Ministry of Health

Locations

Country	Name	City	State
Egypt	Teachers Hospital	Cairo	Please Select

Sponsors (2)

Lead Sponsor	Collaborator
Ain Shams University	Misr International University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in patients' clinical status	Change in clinical status will be assessed daily using six category ordinal scale. The categories were defined as follows: 1) patient discharged, 2) hospitalization not requiring supplemental oxygen, 3) hospitalization requiring supplemental low-flow oxygen, 4) hospitalization requiring high-flow supplemental oxygen, 5) hospitalization requiring invasive mechanical ventilation, 6) death.	Two weeks
Primary	Time to increase in oxygenation	Time to increase in SpO2/FiO2 of 50 or greater compared to the baseline SpO2/FiO2	48 hours
Primary	Duration of hospitalization	Length of hospital stay	Two weeks
Primary	In hospital mortality	Death occurrence during hospitalization	Two weeks
Secondary	Incidence of non-invasive mechanical ventilation	Need for non-invasive mechanical ventilation	Two weeks
Secondary	Duration of non-invasive mechanical ventilation	Time required on non-invasive mechanical ventilation	Two weeks
Secondary	Incidence of invasive mechanical ventilation	Need for invasive mechanical ventilation	Two weeks
Secondary	Duration of invasive mechanical ventilation	Time required on invasive mechanical ventilation	Two weeks
Secondary	Occurrence of secondary infection	Occurrence of sepsis	Two weeks